| Rank | Stock | Price | Vol. Ind. | Dist. Low | New High |
|---|---|---|---|---|---|
| WKN | Symbol | |||||
| 1 | StoneX Group | 126.63 $ | 160.67 % | 67.80 % | 0 Tage |
| A2P8CE | SNEX | |||||
| 2 | Innodata | 70.50 $ | 140.70 % | 441.49 % | 0 Tage |
| 907651 | INOD | |||||
| 3 | Intra-Cellular Therapies | 129.02 $ | 97.66 % | 81.98 % | 0 Tage |
| A1XDTL | ITCI | |||||
| 4 | Grid Dynamics Holdings | 22.40 $ | 82.86 % | 69.76 % | 0 Tage |
| GDYN | |||||
| 5 | Live Nation Entertainment | 154.09 $ | 79.28 % | 66.46 % | 0 Tage |
| A0H0VZ | LYV | |||||
| 6 | Trevi Therapeutics | 4.96 $ | 64.55 % | 110.17 % | 0 Tage |
| TRVI | |||||
| 7 | SpringWorks Therapeutics | 58.31 $ | 299.86 % | 106.70 % | 1 Tage |
| SWTX | |||||
| 8 | H & E Equipment Services | 99.96 $ | 174.93 % | 144.26 % | 1 Tage |
| A0ESPV | HEES | |||||
| 9 | LPL Financial Holdings | 378.62 $ | 100.48 % | 85.22 % | 1 Tage |
| A1JZ6S | LPLA | |||||
| 10 | Interdigital | 216.26 $ | 82.48 % | 66.66 % | 1 Tage |
| A0MWY3 | IDCC | |||||
Already a subscriber? Login
Trevi Therapeutics (TRVI) is a biotech company focusing on the development of Haduvio (oral Nalbuphine ER). Haduvio is a drug being developed by Trevi Therapeutics aimed at helping people suffering from severe and persistent cough, particularly in certain conditions such as idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). IPF...
Samsara [US79589L1061] Piper Sandler upgrades from Neutral to Overweight with a price target of $50 (40% upside potential) The upgrade is justified by the valuation after the stock has declined by 40% in recent weeks. Samsara is described as a high-quality and sustainable growth story with increasing opportunities in artificial intelligence, expanding...
